Tango Therapeutics (TNGX) FCF Margin (2020 - 2025)
Tango Therapeutics (TNGX) recorded quarterly FCF Margin of 58.58% in Q3 2025, up 94.93% quarter-over-quarter from 1154.48% in Q2 2025, and up 22468.0% on a YoY basis from N/an in Q3 2024.
Tango Therapeutics (TNGX) FCF Margin (2020 - 2025) Analysis & Trends
Tango Therapeutics' FCF Margin history runs 6 years deep, the most recent figure standing at 58.58% for Q3 2025.
- In Q3 2025, FCF Margin rose 22468.0% year-over-year to 58.58%; the TTM figure through Mar 2026 stood at 250.11% (up 8155.0% YoY), while the FY2025 annual figure was 224.31%, up 9007.0% from the prior year.
- FCF Margin was 58.58% for Q3 2025 at Tango Therapeutics, up from 1154.48% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 42.53% in Q2 2021 to a low of 1154.48% in Q2 2025.
- Historically, FCF Margin has averaged 433.68% across 5 years, with a median of 367.62% in 2022.
- The sharpest annual moves came in 2023 and 2025: FCF Margin soared 37763 bps in 2023, then plunged 103409 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 291.1% in 2021, then tumbled by 57 bps to 457.14% in 2022, then dropped by 12 bps to 509.91% in 2023, then plunged by 78 bps to 908.38% in 2024, then soared by 94 bps to 58.58% in 2025.
- The last three FCF Margin figures came in at 58.58% (Q3 2025), 1154.48% (Q2 2025), and 774.26% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -58.58% |
| Jun 30, 2025 | -1,154.48% |
| Mar 31, 2025 | -774.26% |
| Dec 31, 2024 | -908.38% |
| Sep 30, 2024 | -283.26% |
| Jun 30, 2024 | -120.39% |
| Mar 31, 2024 | -588.04% |
| Dec 31, 2023 | -509.91% |
| Sep 30, 2023 | -290.26% |
| Jun 30, 2023 | -174.46% |
| Mar 31, 2023 | -610.42% |
| Dec 31, 2022 | -457.14% |
| Sep 30, 2022 | -367.62% |
| Jun 30, 2022 | -552.09% |
| Mar 31, 2022 | -523.88% |
| Dec 31, 2021 | -291.10% |
| Sep 30, 2021 | -317.43% |
| Jun 30, 2021 | -42.53% |
| Mar 31, 2021 | -215.75% |
| Dec 31, 2020 | -5.66% |